Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒‒ Expects ...

Under the leadership of Mr. Todisco, CorMedix has evolved from a single product, development stage company into a multi-product, diversified commercial operation with positive cashflow and a strong ...

After two dialysis patients died at a Kerala government hospital, concerns mount over infection and mortality risks in people ...

For many dialysis patients, the whole idea can feel extremely confusing and even a bit scary because the process isn't always explained clearly. Sometimes the patient themselves may not remember the ...

CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...

CorMedix sees its revenue contracting significantly in 2026. CRMD shares crashed about 35% on the announcement today.

CorMedix on Thursday guided for revenue between $300 million and $320 million for fiscal 2026, compared with $310 million in net revenue for fiscal 2025, according to the company's unaudited ...

Preventogen™ eradicated Candida auris antibiotic-resistant strain by 99.99% at 30, 90 and 120 seconds with a formidable 5.61 log reduction. ST. LOUIS, MO / ACCESS Newswire / January 7, 2026 / ...

This presentation should be read in conjunction with the press release discussing the company's operating results and ...

The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year. ・The company expects adjusted EBITDA for 2026 to be between $100 million and ...

Q2 2026 Earnings Call Transcript January 6, 2026 AngioDynamics, Inc. misses on earnings expectations. Reported EPS is ...

The first days were hard. I was in pain and emotionally exhausted. I worried about my wife (and kidney donor), Teneshia, who was recovering down the hall. I felt uncertain about the future. Healing ...